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In the absence of clinical breakpoints (CBP), epidemiological cutoff values (ECVs) are useful to separate wild-type (WT) isolates
(without mechanisms of resistance) from non-WT isolates (those that can harbor some resistance mechanisms), which is the
goal of susceptibility tests. Sensititre YeastOne (SYO) is a widely used method to determine susceptibility of Candida spp. to an-
tifungal agents. The CLSI CBP have been established, but not for the SYOmethod. The ECVs for four azoles, obtained usingMIC
distributions determined by the SYOmethod, were calculated via five methods (three statistical methods and based on theMIC50
andmodal MIC). Respectively, the median ECVs (in mg/liter) of the five methods for fluconazole, itraconazole, posaconazole,
and voriconazole (in parentheses: the percentage of isolates inhibited byMICs equal to or less than the ECVs; the number of iso-
lates tested) were as follows: 2 (94.4%; 944), 0.5 (96.7%; 942), 0.25 (97.6%; 673), and 0.06 (96.7%; 849) for Candida albicans; 4
(86.1%; 642), 0.5 (99.4%; 642), 0.12 (93.9%; 392), and 0.06 (86.9%; 559) for C. parapsilosis; 8 (94.9%; 175), 1 (93.7%; 175), 2
(93.6%; 125), and 0.25 (90.4%; 167) for C. tropicalis; 128 (98.6%; 212), 4 (95.8%; 212), 4 (96.0%; 173), and 2 (98.5; 205) for C.
glabrata; 256 (100%; 53), 1 (98.1%; 53), 1 (100%; 33), and 1 (97.9%; 48) for C. krusei; 4 (89.2%; 93), 0.5 (100%; 93), 0.25 (100%;
33), and 0.06 (87.7%; 73) for C. orthopsilosis. All methods included>94% of isolates and yielded similar ECVs (within 1 dilu-
tion). These ECVs would be suitable for monitoring emergence of isolates with reduced susceptibility by using the SYOmethod.
An important cause of morbidity andmortality in hospitalizedpatients with serious underlying conditions is candidemia,
which is related to high health care costs (1, 2). However, the
number of antifungal agents for candidemia treatment is small
(azoles, echinocandins, flucytosine, and polyenes), and treatment
failures have been reported. It is anticipated that antifungal sus-
ceptibility tests will be performed, particularly when this failure
occurs, and additional epidemiological studies need to be per-
formed. The Sensititre YeastOne (SYO) method is one of the an-
tifungal susceptibility tests most frequently used in clinical labo-
ratories. Clinical breakpoints (CBP) recommended by the CLSI
have to be applied when tests are performed using that method-
ology. However, CBP are not available for the SYOmethod; there-
fore, in their absence, epidemiological cutoff values (ECVs) are
useful for separation of isolates without mechanisms of resistance
(wild-type [WT] fromnon-wild-type isolates, those thatmay har-
bor some resistance mechanisms [non-WT]), which is the goal of
susceptibility tests. Several methods have been described to calcu-
late ECVs; for instance, Arendrup et al. (3) estimated the ECVs as
2-fold dilution steps higher than theMIC50 (theMIC that inhibits
50% of isolates); Rodriguez-Tudela et al. (4) worked with 2-fold
dilutions above the modal MIC; Cantón et al. (5), Kronvall (6),
and Turnidge et al. (7) calculated the ECVs by using statistical
methods, and the latter two study groups concluded that the val-
ues thus obtained fit well with those determined through the
MIC50 or modal MICmethods. We previously reported the ECVs
of echinocandins, amphotericin B, and flucytosine based on this
methodology for the SYO method (5), and as an extension we
have now determined the ECVs for the azole agents used for treat-
ment of invasive Candida infections as recommended in the cur-
rent guidelines (of the Infectious Diseases Society of America,
FDA, etc.) (8).
The aims of this study were to (i) define theWTMIC distribu-
tions of fluconazole (FZ), itraconazole (ITR), posaconazole
(POS), and voriconazole (VOR) by the SYO method for four of
the most common and two less common Candida species that
cause bloodstream infections, (ii) propose the ECVs for each spe-
cies-drug combination, and (iii) compare the ECVs obtained by
the five methods with each other and also with those obtained
using the CLSI methodology.
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MATERIALS AND METHODS
Isolates. A total of 2,119 Candida bloodstream isolates were tested: 857
isolates were isolated from just one center (334 C. albicans, 315 C. parap-
silosis, 56 C. glabrata, 62 C. tropicalis, 63 C. orthopsilosis, and 27 C. krusei)
from January 1995 to December 2010, and 1,262 isolates (610 C. albicans,
327 C. parapsilosis, 156 C. glabrata, 113 C. tropicalis, 30 Candida orthop-
silosis, and 26 C. krusei) were obtained from 43 public tertiary care hospital
laboratories, which represent all Spanish geographical areas (FUNGEMYCA
Epidemiological Study). Isolateswere recovered fromJanuary 2009 toFebru-
ary 2010. Each isolate represented one infectious episode per patient andwas
identified by standard methods in each center, stored in a water suspension,
and sent to the reference center (Hospital Universitario La Fe, Valencia,
Spain) for posterior studies. C. parapsilosis and C. orthopsilosis strains were
identified by amolecularmethodology described elsewhere (9). Three azole-
resistantCandida strainswithdifferentmechanismsof resistancewereused to
assess the accuracy of the ECVs calculated (Table 1) (10, 11).
Antifungal susceptibility testing. Susceptibility tests were performed
at the participating hospitals on the first isolate from each candidemia
episode by using the microdilution colorimetric SYO method, with the
SYO-09 panel (TREK Diagnostic Systems, Cleveland, OH), as instructed
in the commercial guidelines. The quality control strains C. krusei ATCC
6258 and C. parapsilosis ATCC 22019 were first tested in each participat-
ing laboratory, and results were sent to the reference center. All MIC
values were within the expected ranges.
Definitions. The definitions of the WT population and ECV were
those reported previously by other authors (4, 12, 13); briefly, a WT or-
ganism was defined as a strain that did not harbor any acquired or muta-
tional resistance mechanism to the particular antifungal agent being ex-
amined.
The ECV is the highest MIC value for the WT population. It is calcu-
lated by taking into account theMIC distribution, themodalMIC of each
distribution, and the inherent variability of the test (usually within one
doubling dilution), and it should encompass95% of isolates. The num-
ber of isolates needed to calculate a representative ECV was not estab-
lished, but there is a consensus among experts that recommends at least 50
strains from at least three to five different laboratories be included.
Statistical analysis. Data were analyzed with R software (version
2.14.2) (14). Both on-scale and off-scale MICs were included, with the
values left unchanged. In order to approach a normal distribution, the
MICs were converted to log2 values. Statistical ECVs were calculated fol-
lowing the methods described by Turnidge et al., by Kronvall, and by the
clustering method using the Mclust Library for R (version 3.4.11), as
previously described (5–7). Since the ECVs estimated fell within a contin-
uous scale, values were rounded to the nearest highest dilution after re-
conversion to concentration units.
RESULTS AND DISCUSSION
The MIC data for each species, including those species with few
isolates (less than 100), and each antifungal agent were obtained
frommore than five laboratories. The MIC results of the antifun-
gal agents tested, which have been reported elsewhere (15), were
TABLE 1 Resistance mechanisms and MICs of azole agents determined
with SYO for azole-resistant Candida spp.
Species Strain
Mechanism(s) of
resistance
MIC (g/ml)
FZ ITR POS VOR
C. parapsilosis BC014RVRC Mutation K873N in
Mrr1
64 0.125 0.125 0.5
C. albicans 95-190 Overexpression CDR1,
CDR2, ERG11,
and MDR1
256 16 8 8
C. parapsilosis BC014RFCZ Mutation G583R in
Mrr1
64 0.125 0.06 0.125
TABLE 2Wild-type MIC distributions of azole agents for six species of Candida based on the Sensititre YeastOne method
Agent Species
No. of isolates with MIC (g/ml) of:
Total no.
of isolates0.008 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256
Fluconazole C. albicans 9 98 302 340 118 24 13 10 2 2 1 6 19 944
C. parapsilosis 1 14 37 137 190 103 71 55 18 12 4 642
C. tropicalis 2 10 32 68 38 10 6 1 8 175
C. glabrata 3 4 17 25 37 44 51 15 6 7 3 212
C. krusei 1 3 4 7 20 18 53
C. orthopsilosis 1 3 17 39 15 8 5 3 2 93
Itraconazole C. albicans 36 131 204 275 225 35 5 2 1 4 24 942
C. parapsilosis 8 40 97 186 218 79 10 4 642
C. tropicalis 2 7 15 64 54 16 6 4 2 5 175
C. glabrata 4 3 3 26 51 65 38 9 4 2 7 212
C. krusei 1 2 6 25 13 5 1 53
C. orthopsilosis 1 2 14 30 31 15 93
Posaconazole C. albicans 69 177 210 150 47 4 4 1 2 9 673
C. parapsilosis 21 80 124 91 52 19 1 3 1 392
C. tropicalis 4 5 8 16 27 42 12 3 1 7 125
C. glabrata 2 3 7 10 23 45 59 15 2 7 173
C. krusei 1 1 2 20 6 3 33
C. orthopsilosis 4 9 9 10 1 33
Voriconazole C. albicans 688 95 27 11 8 5 2 3 8 2 849
C. parapsilosis 185 143 92 66 45 15 7 5 1 559
C. tropicalis 3 19 44 37 35 13 6 1 1 5 3 167
C. glabrata 10 8 13 39 39 62 16 10 5 2 1 205
C. krusei 1 1 16 21 6 2 1 48
C. orthopsilosis 27 16 11 10 5 3 1 73
Cantón et al.
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similar to those observed by other authors who have used the SYO
method (16–18). Table 2 describes the WT MIC distributions of
the four azoles tested. All MIC distributions were typical for WT
organisms and covered three to five 2-fold dilution steps sur-
rounding the modal MIC, except those of ITR (n 93) and POS
(n 33) for C. orthopsilosis, for which only 1 dilution was above
the modal MIC. Table 3 depicts the ECVs obtained with the SYO
method, as determined with the five methods mentioned above
(three statistical and two using dilutions above the MIC50 or the
modal MIC), the median ECVs of the five methods, and those
published by Pfaller et al. for the CLSI. Although the fluconazole
MIC for C. krusei is not recommended, the ECV was included in
this table because this drug is incorporated in the SYO 09 panel
and for comparison with the CLSI ECVs. The same was true for
the echinocandin ECVs; the statistical method proposed by
Turnidge et al. gave lower ECVs than those proposed by Kronvall,
although 70.8% were within 1 dilution. There was only a differ-
ence of three 2-fold dilutions for the ECVs of VOR forC. tropicalis
(0.25 versus 2 mg/liter) and C. orthopsilosis (0.06 versus 0.5 mg/
liter). By the clustering method, 75% of ECVs were within one
2-fold dilution of those obtained with Turnidge et al.’s method;
the greatest differences were three 2-fold dilutions for the ECVs of
FZ for C. tropicalis (8 versus 64 mg/liter), and the rest of the ECVs
were within the 2-fold dilutions. The median ECVs were, in gen-
eral, equal to or two 2-fold dilutions higher than those of the
CLSI value, with the exception of POS for C. tropicalis, for
which the ECV was four 2-fold dilutions higher (2 versus 0.12
mg/liter). The ECVs obtained with the modal MIC and MIC50
were in general lower than the values obtained when we applied
the statistical methods; nevertheless, 100 and 91.7% of the
cases, respectively, were within 1 dilution of the median ECV
(Tables 3 and 4). The MIC values determined with the SYO
method for Candida strains with different mutations used to
confirm the validity of the ECVs are shown in Table 1; all meth-
ods used to calculate the ECVs classified the strains harboring
mutations as non-WT.
The ECVs obtained by the different methods were compared
with each other and with those reported based on the CLSI meth-
odology. Therefore, the median values for the five methods ana-
lyzed were those put forward as the tentative ECVs. Table 4 shows
the level of agreement (within one and two 2-fold dilutions) be-
tween methods, as well as the cases where the difference was
greater than two 2-fold dilutions, and it also includes the Pear-
son’s correlation values. In general, the agreement was 95.7%.
The most repetitive exception was the ECV of POS for C. tropica-
TABLE 3 Comparison of ECVs obtained for the four azole agents when we used the different methods
Species
No. of
isolates tested Agent
ECV obtained by indicated method (%)a
MIC50 2
dilutions
Modal MIC 2
dilutions
Turnidge
et al. Kronvall Clustering
Median of all
studied methods CLSIb
C. albicans 944 FZ 2 (94.4) 2 (94.4) 2 (94.4) 8 (96.8) 2 (94.4) 2 (94.4) 0.5 (98.1)
942 ITR 0.25 (96.2) 0.25 (96.2) 0.5 (96.7) 1 (96.9) 2 (96.9) 0.5 (96.7) 0.12 (95.0)
673 POS 0.12 (97.0) 0.12 (97.0) 0.25 (97.6) 0.5 (98.2) 0.5 (98.2) 0.25 (97.6) 0.06 (98.4)
849 VOR 0.03 (95.4) 0.06 (96.7) 0.12 (97.6) 0.12 (97.6) 0.06 (96.7) 0.06 (96.7) 0.03 (99.0)
C. parapsilosis 642 FZ 4 (86.1) 4 (86.1) 8 (94.7) 16 (97.5) 4 (86.1) 4 (86.1) 2 (93.2)c
642 ITR 0.25 (97.8) 0.5 (99.4) 0.5 (99.4) 0.5 (99.4) 0.25 (97.8) 0.5 (99.4) 0.5 (99.7)
392 POS 0.12 (93.9) 0.12 (93.9) 0.25 (98.7) 0.5 (99.0) 0.12 (93.9) 0.12 (93.9) 0.25 (99.3)c
559 VOR 0.06 (86.9) 0.06 (86.9) 0.06 (86.9) 0.25 (97.7) 0.03 (75.1) 0.06 (86.9) 0.12 (97.8)c
C. tropicalis 175 FZ 4 (91.4) 4 (91.4) 8 (94.9) 32 (94.9) 64 (94.9) 8 (94.9) 2 (98.4)
175 ITR 0.5 (90.3) 0.5 (90.3) 1 (93.7) 4 (96) 2 (96) 1 (93.7) 0.5 (97.8)
125 POS 1 (93.6) 1 (93.6) 2 (93.6) 4 (94.4) 4 (94.4) 2 (93.6) 0.12 (97.8)
167 VOR 0.25 (90.4) 0.12 (82.6) 0.25 (90.4) 2 (94.6) 1 (94.0) 0.25 (90.4) 0.06 (97.3)
C. glabrata 212 FZ 32 (92.5) 64 (95.3) 128 (98.6) 128 (98.6) 128 (98.56) 128 (98.6) 32 (91.5)
212 ITR 2 (93.9) 2 (93.9) 4 (95.8) 8 (96.7) 4 (95.8) 4 (95.8) 2 (95.2)
173 POS 2 (94.8) 4 (96.0) 8 (100) 8 (100) 2 (94.8) 4 (96.0) 2 (96.1)
205 VOR 0.5 (91.2) 1 (96.1) 2 (98.5) 2 (98.5) 2 (98.5) 2 (98.5) 0.5 (90.4)
C. krusei 53 FZ 256 (100) 256 (100) 128 (100) 256 (100) 128 (100) 256 (100) 64 (99.8)
53 ITR 1 (98.1) 1 (98.1) 2 (98.1) 2 (98.1) 1 (98.1) 1 (98.1) 1 (99.0)
33 POS 1 (100) 1 (100) 2 (100) 2 (100) 1 (100) 1 (100) 0.5 (99)
48 VOR 1 (97.9) 1 (97.9) 1 (97.9) 1 (97.9) 1 (97.9) 1 (97.9) 0.5 (99.4)
C. orthopsilosis 93 FZ 4 (89.2) 4 (89.2) 8 (94.6) 32 (97.9) 2 (80.7) 4 (89.2) 2 (98)
93 ITR 0.25 (100) 0.5 (100) 0.5 (100) 0.5 (100) 0.5 (100) 0.5 (100) NDd
33 POS 0.25 (100) 0.5 (100) 0.5 (100) 0.25 (100) 0.12 (97.0) 0.25 (100) 0.25 (97.1)
73 VOR 0.06 (87.7) 0.03 (74.0) 0.06 (87.7) 0.5 (100) 0.06 (87.7) 0.06 (87.7) 0.06 (98)
a Percentage of isolates for which the MIC was less than or equal to the ECV (in g/ml).
b Data were obtained from references 19 to 22.
c C. parapsilosis complex.
d ND, not determined.
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lis, for which the CLSI ECV was 3 to 5 dilutions lower than those
obtained with the other methods.
The Pearson’s correlation between the median ECV from the
SYO method and each of the other methods was very good
(0.94), except for that from the clustering method (0.89) (Table
4). In a comparison of the ECVs from the CLSImethodwith those
obtained with the SYO method for each antifungal agent, FZ
showed the best correlation (0.96), and whenwe compared spe-
cies, the lowest correlation was for C. tropicalis. This species also
showed the lowest Pearson’s correlation for the echinocandin
ECVs with the SYO method (5).
The ECVs were also calculated for the distribution of the two
sources of isolates individually, i.e., 1,262 isolates from 43 labora-
tories and 857 isolates from 1 center. The same result occurred
with the echinocandin ECVs, and the results obtained were, in
general, the same as those found with all 2,119 isolates, or they fell
within one 2-fold dilution, which is in agreement with the work of
Turnidge et al. and Kronvall, who reported that their methods are
also valid for data sets generated by a single laboratory andmethod
(6, 7). Just as we emphasized in the determination of echinocan-
din ECVs with the SYO method, it is difficult to establish which
statistical method best defines the ECV, due to the scarcity of
resistant isolates. Perhaps the optimal method depends on the
heterogeneity of the agent’sMICdistributions, since different spe-
cies may have different numbers of subpopulations and, conse-
quently, different MIC distribution shapes (unimodal, bimodal,
or multimodal). In fact, the majority of differences, in general,
were only within one 2-fold dilution, and furthermore, the Pear-
son’s correlation values between methods were good, and so we
propose that the median values of the five methods used in this
evaluation be considered the tentative ECVs for the SYOmethod.
Moreover, independently of the method used, a 5% risk of mis-
identification was always assumed (in fact, it is 2.5%, because the
distribution has two tails). In general, all ECVs determined with
the five methods included94% of isolates; the exceptions were
the ECVs of FZ and VOR for C. parapsilosis and C. orthopsilosis.
Other authors have also reported ECVs that did not include 95%
of isolates (19, 20).
The tentative ECVs proposed are very similar to those of the
CLSI; the differences in some values are the same as those found
when comparing MIC values obtained with the CLSI or SYO
methodology (16–18). The advantage of this study is that all iso-
lates used were obtained from patients without prior treatment
with any of the antifungal agents tested; thus, the outlier isolates
probably represented mutant strains. The data came from 43 lab-
oratories, and all isolates were obtained from blood cultures.
Among the limitations of the study are the small numbers of C.
krusei and C. orthopsilosis isolates tested, but we have kept the
tentative ECVs for these species, for comparison amongmethods.
Moreover, all isolates came from just one country, and so these
values may not be completely representative but could be shared
with other data sets in the future to establish forthcoming ECVs
with the SYO method. The low number of strains with known
mechanisms of resistance was another limitation. Nevertheless,
these data have corroborated the ECVs obtained.We propose, for
the first time, tentative ECVs for the SYOmethod and azole agents
to help in monitoring the emergence of isolates with decreased
susceptibilities to these agents, which is the aim of susceptibility
tests and also of generation of ECVs.
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